Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Status Completed

Clinical Trial Summary

The purpose of this study is to estimate the safety of ex vivo expanded haploidentical natural killer (NK) cells for patients with leukemia.

Clinical Trial Description

Immunotherapy with natural killer (NK) cells may improve the results of treatment for patients with cancer. However, for better efficiency high doses of NK cells are required. For this purpose, NK cells were expanded in the presence of feeder K562 cells gene-modified for expression 4-1BBL and membrane bound IL-21. In the result of expansion, large number of activated NK cells are obtained. Protocol of immunotherapy includes conditioning (fludarabine + cyclophosphamide or any other protocol of chemotherapy) followed by expanded NK cells intravenous infusion. To sustain proliferation of donor NK cells in vivo patients receive 6 doses of Il-2 every second day. 10 patients will be enrolled in phase I to test different doses of NK cells: 20, 50, 70, 100 and >100 x 10^6/kg. ;

Study Design

Related Conditions & MeSH terms

Acute Disease
Leukemia
Leukemia, Acute Lymphoblastic
Leukemia, Acute Myeloid
Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT04327037
Study type	Interventional
Source	Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Contact
Status	Completed
Phase	Phase 1
Start date	January 2, 2019
Completion date	June 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Unknown status	`NCT02360930` - Vincristine PK and PD in the AYA Population Compared to Younger Children	N/A
Recruiting	`NCT05306301` - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients	Phase 2
Not yet recruiting	`NCT06101381` - CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma	Phase 1/Phase 2
Terminated	`NCT02935543` - CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL	Phase 2
Active, not recruiting	`NCT05440409` - CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed	`NCT02393859` - Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)	Phase 3
Recruiting	`NCT05064787` - Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy	N/A
Terminated	`NCT02435550` - iCare for Cancer Patients	N/A
Completed	`NCT02799147` - GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia	Phase 1/Phase 2
Terminated	`NCT02580981` - Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses	N/A
Recruiting	`NCT04307576` - A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	Phase 3
Recruiting	`NCT04942730` - Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)	Phase 2
Terminated	`NCT01761682` - Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Terminated	`NCT02349178` - Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT	Phase 2
Recruiting	`NCT04209244` - Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia	N/A
Recruiting	`NCT03911128` - A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
No longer available	`NCT00590915` - Erwinase Master Treatment Protocol	N/A